Whitener Capital Management’s Ligand Pharmaceuticals LGND Stock Holding History

Whitener Capital Management’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-160	Closed	-$11K	–	501
2019 Q2	$11K	Hold	160	–	–	0.01%	339
2019 Q1	$12K	Buy	160 +80	+100%	+$6.06K	0.01%	320
2018 Q4	$6K	Hold	80	–	–	﹤0.01%	352
2018 Q3	$13K	Buy	+80	New	+$12.1K	0.01%	315
2018 Q2	–	Sell	-80	Closed	-$8K	–	274
2018 Q1	$8K	Hold	80	–	–	0.01%	351
2017 Q4	$6K	Buy	+80	New	+$6.93K	0.01%	359

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Whitener Capital Management's LGND Position: Q3 2019 in Review

Whitener Capital Management sold out of Ligand Pharmaceuticals (LGND) in Q3 2019, closing a stake of 160 shares — an estimated $11K sold.

Whitener Capital Management first reported a position in LGND in Q4 2017 and held it in 6 quarters. The position peaked at $13K in Q3 2018. 275 funds tracked by Wall St. Rank hold LGND as of Q3 2019.

Whitener Capital Management reported no remaining Ligand Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Whitener Capital Management sold 160 Ligand Pharmaceuticals shares in Q3 2019, an estimated $11K.
Whitener Capital Management first reported a position in Ligand Pharmaceuticals in Q4 2017 and held it in 6 quarters.
Whitener Capital Management's Ligand Pharmaceuticals position peaked at $13K in Q3 2018.
275 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2019.

Based on Whitener Capital Management's 13F filing for Q3 2019, filed 7 Nov 2019.